GSK (GSK) RNS Announcements

Add to Alert list
Date Time Source Announcement
15 Jul 2025 03:30 PM
RNS
Director/PDMR Shareholding
15 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
14 Jul 2025 03:30 PM
RNS
Director/PDMR Shareholding
14 Jul 2025 07:00 AM
RNS
GSK submits Arexvy for adults 18-49 AIR to FDA
14 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
11 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
10 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
09 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
08 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
07 Jul 2025 04:00 PM
RNS
GSK completes acquisition of efimosfermin for SLD
07 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
04 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
03 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
02 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
01 Jul 2025 03:00 PM
RNS
Total Voting Rights
01 Jul 2025 07:00 AM
RNS
Transaction in Own Shares
30 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
27 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
26 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
25 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
24 Jun 2025 03:30 PM
RNS
Director/PDMR Shareholding
24 Jun 2025 03:00 PM
RNS
Director Declaration
24 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
23 Jun 2025 05:50 PM
RNS
Replacement - Director/PDMR Shareholding
23 Jun 2025 03:30 PM
RNS
Director/PDMR Shareholding
23 Jun 2025 08:30 AM
RNS
Replacement RNS: Linerixibat file accepted by EMA
23 Jun 2025 08:18 AM
RNS
GSK Submits Arexvy for adults 18+ with EMA
23 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
20 Jun 2025 07:00 AM
RNS
Arexvy filed in Japan for 18-49 at increased risk
20 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
19 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
18 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
17 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
16 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
13 Jun 2025 03:30 PM
RNS
Director/PDMR Shareholding
13 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
13 Jun 2025 07:00 AM
RNS
GSK submits Arexvy for adults 18+ with EMA
12 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
11 Jun 2025 03:30 PM
RNS
Director/PDMR Shareholding
11 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
10 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
09 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
06 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
05 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
04 Jun 2025 07:00 AM
RNS
GSK - second tranche of share buyback programme
04 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
03 Jun 2025 07:00 AM
RNS
Transaction in Own Shares
02 Jun 2025 03:30 PM
RNS
Director/PDMR Shareholding
02 Jun 2025 03:00 PM
RNS
Total Voting Rights
02 Jun 2025 07:00 AM
RNS
Linerixibat file accepted for review by US FDA

GSK PLC, known as GSK, is a renowned multinational pharmaceutical and biotechnology company with its global headquarters in London. Traded as GSK on the London Stock Exchange (LSE), it has a rich history that traces back to the establishment of Plough Court Pharmacy in London in 1715. Over the centuries, GSK has grown from a handful of individual founders into a company of over 69,000 people.

The company's journey includes the development of 15 first-in-class or combination vaccines and pioneering medications in respiratory, antibiotics, antivirals, and oncology. GSK has been a leader in medicines that advance the management of asthma and chronic obstructive pulmonary disease (COPD) for 50 years.

In 2000, Glaxo Wellcome and SmithKline Beecham merged to form the modern GSK, becoming a key player on the LSEG. Today, GSK continues to shape the global healthcare landscape, committed to defeating diseases that impact people's health. This evergreen company remains at the forefront of the pharmaceutical industry, embodying its founding principle of improving the quality of human life by enabling people to do more, feel better, and live longer.

GSK share price launched at 346p in 1989. 

UK 100

Latest directors dealings